- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04048616
Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults
January 9, 2024 updated by: Lisa Ceglia, Tufts University
Whether higher dietary protein benefits skeletal muscle health in older adults remains an ongoing area of investigation.
This study will determine whether adding an alkaline salt supplement, potassium bicarbonate, to reduce the dietary acid load of a high protein diet can further enhance the beneficial impact of a high protein diet alone on muscle performance and mass in older underactive adults on baseline low protein diet.
Study Overview
Status
Completed
Conditions
Detailed Description
With aging, skeletal muscle mass and performance decline leading to an increased risk of falls and physical disability.
There is ongoing research on whether increasing dietary protein intake in older adults improves indices of muscle health and thus translates to a reduction in physical disability.
A main concern is that high protein results in a large dietary acid load from the breakdown of protein to acidogenic byproducts, which could in turn promote muscle degradation particularly in older adults with age-related declines in renal excretion of acid.
The scientific premise of this project is that the balance between the amount of protein in the diet (anabolic component) and the net acid load of the diet (catabolic component) in part determines whether the diet as a whole has a net anabolic or catabolic effect on muscle.
Preliminary data have suggested that a daily alkaline salt supplement (potassium bicarbonate, KHCO3) lowered the dietary acid load and improved lower extremity muscle power in postmenopausal women.
The investigator's central hypothesis is that higher protein intake plus a neutralizing alkaline salt will have additive effects on muscle performance and mass in older adults to either intervention alone.
To test the hypothesis, the investigators will conduct a randomized, double-blind, placebo-controlled, 2x2 factorial study in which underactive men and women age 65 and older on baseline lower protein diets will be enrolled.
Participants will assigned to one of four groups: either a whey protein supplement (to raise protein intake to 1.5 g/kg/d) with or without KHCO3 81 mmol/d or an isocaloric placebo supplement with or without KHCO3 81 mmol/d for 24 wks.
The primary outcome is lower extremity muscle power at 24 weeks.
Secondary outcomes are lower extremity muscle power at 12 weeks, muscle endurance at 12 and 24 weeks, physical performance at 24 weeks, lean mass at 24 weeks, and 24-hr urinary nitrogen excretion adjusted for nitrogen intake at 24 weeks.
Exploratory outcomes will include a measure of muscle mass - D3-creatine dilution - and how it correlates with lean mass.
Changes in these outcomes will be compared in the 4 groups.
If successful, this research would represent a meaningful step in defining the circumstances under which protein has its greatest anabolic benefit.
Study Type
Interventional
Enrollment (Actual)
141
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Ceglia, MD MS
- Phone Number: 617-556-3085
- Email: lisa.ceglia@tufts.edu
Study Contact Backup
- Name: Elise Reitshamer
- Phone Number: 617-556-3265
- Email: elise.reitshamer@tufts.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- ability to sign informed consent form
- ambulatory community-dwelling men and women
- age 65 years and over
- habitual dietary intake of protein of ≤0.8 g/kg/d
- underactive
- estimated glomerular filtration rate ≥ 50 ml/min/1.73 m2
Exclusion Criteria:
- participation in a diet or intensive exercise program during the study
- vegetarian (no animal protein)
- oral glucocorticoid use for > 10 days in the last 3 months
- anabolic and gonadal hormones in the last 6 months
- Tamoxifen/raloxifene in the last 6 months
- regular use of alkali-producing antacids (> 3 times per week)
- potassium-containing supplements or products
- non-steroidal anti-inflammatory medications >3 times per week
- antacids containing calcium carbonate, aluminum hydroxide, magnesium hydroxide, or calcium acetate
- insulin
- sulfonylureas
- SGLT2 inhibitors
- a lower extremity fracture in the last year
- kidney stones in the past 5 years
- hyperkalemia
- elevated serum bicarbonate
- hypercalcemia
- uncontrolled diabetes mellitus defined as having fasting blood >150 or hemoglobin A1c >8%
- untreated thyroid or parathyroid disease
- significant immune disorder
- current unstable heart disease
- Crohn's disease
- active malignancy or cancer therapy in the last year
- alcohol use exceeding 2 drinks/day
- current peptic ulcers or esophageal stricture
- other condition or abnormality in screening labs, at discretion of the study physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: whey protein isolate + KHCO3
1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
|
one 15-25 gm (based on body weight) protein packet three times a day with each meal
two 13.5 mmol capsules three times a day with each meal
|
Active Comparator: whey protein isolate + microcrystalline cellulose
1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
|
one 15-25 gm (based on body weight) protein packet three times a day with each meal
identical placebo capsule
|
Active Comparator: maltodextrin powder + KHCO3
isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
|
two 13.5 mmol capsules three times a day with each meal
isocaloric placebo powder
|
Placebo Comparator: maltodextrin powder + microcrystalline cellulose
isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
|
identical placebo capsule
isocaloric placebo powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lower extremity muscle power
Time Frame: 24 weeks
|
measure of muscle power using a double leg press
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lower extremity muscle power
Time Frame: 12 weeks
|
measure muscle power using double leg press
|
12 weeks
|
isokinetic leg extension strength and endurance
Time Frame: 12 and 24 weeks
|
measure knee extension strength, torque and fatigability using Biodex Isokinetic Dynamometer
|
12 and 24 weeks
|
handgrip strength
Time Frame: 24 weeks
|
measure strength using grip strength dynamometer
|
24 weeks
|
appendicular lean body mass
Time Frame: 24 weeks
|
Dual energy X-ray absorptiometry (DXA) lean mass of arms plus legs divided by height squared
|
24 weeks
|
physical performance battery
Time Frame: 24 weeks
|
measure performance based on Health Aging and Body Composition-Physical Performance Battery
|
24 weeks
|
24 hour urinary nitrogen excretion to nitrogen intake
Time Frame: 24 weeks
|
measure based on 24 hour urine and 24 hour diet recall
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
D3-creatine dilution (exploratory)
Time Frame: 24 weeks
|
measure of total body muscle mass
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lisa Ceglia, MD MS, Tufts Medical Center and Tufts University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2019
Primary Completion (Actual)
December 21, 2023
Study Completion (Actual)
December 21, 2023
Study Registration Dates
First Submitted
August 5, 2019
First Submitted That Met QC Criteria
August 6, 2019
First Posted (Actual)
August 7, 2019
Study Record Updates
Last Update Posted (Actual)
January 10, 2024
Last Update Submitted That Met QC Criteria
January 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3010
- 1R01AG055443-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Loss
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States
-
United States Army Research Institute of Environmental...Tufts UniversityCompletedMuscle Loss | Muscle AnabolismUnited States
-
Zhejiang UniversityHuashan Hospital; West China Hospital; The Affiliated Hospital of Qingdao University and other collaboratorsNot yet recruitingLiver Transplantation | Muscle Loss | Muscle Quality
-
Göteborg UniversityCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Orient Europharma Co., Ltd.Completed
-
Lancaster UniversityCompleted
-
Investigación en Hemofilia y FisioterapiaCompleted
-
The University of Texas Medical Branch, GalvestonNational Space Biomedical Research InstituteCompleted
Clinical Trials on whey protein isolate
-
Musclegen Research, Inc.CompletedAbsorption; Disorder, Protein | Analysis, Event History
-
University of WestminsterCoventry UniversityCompletedAppetite and General Nutritional DisordersUnited Kingdom
-
NestléCompleted
-
Federal University of Health Science of Porto AlegreCompleted
-
University of FloridaCompletedRenal Failure | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
Syracuse UniversityDairy Research InstituteCompletedBlood PressureUnited States
-
Nova Southeastern UniversityImmunotec Inc.CompletedAutism Spectrum DisordersUnited States
-
University Hospitals Cleveland Medical CenterCompletedDiabetes Mellitus, Type 1 | Hyperglycemia, PostprandialUnited States
-
Mette HansenAker Biomarine Antarctic ASCompletedHuman NutritionDenmark
-
University of ArkansasCompleted